{
    "code": "52027104",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027104",
    "time": "2022-05-27 03:32:47",
    "許可證字號": "衛部藥輸字第027104號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/05\/04",
    "發證\/登錄日期": "106\/05\/04",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202710406",
    "中文品名": "愛乳適 膠囊125毫克",
    "英文品名": "IBRANCE Capsules 125 mg",
    "適應症": "1. 對於荷爾蒙受體為陽性、第二型人類表皮生長因子接受體(HER2)呈陰性之局部晚期或轉移性乳癌之婦女或男性，IBRANCE 可與芳香環轉化酶抑制劑(aromatase inhibitor)合併使用。\r\n2. 對於荷爾蒙受體為陽性、第二型人類表皮生長因子接受體(HER2)呈陰性之局部晚期或轉移性乳癌之病人，IBRANCE 可合併fulvestrant 用於先前曾接受過內分泌治療者。\r\n說明：停經前\/停經前後(pre\/perimenopause)婦女，接受內分泌治療應合併黃體生成素-釋放激素(luteinizing hormone-releasing hormone；LHRH)致效劑。",
    "劑型": "130膠囊劑",
    "包裝": "2-1000粒鋁箔盒裝 塑膠瓶裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "新成分",
    "監視期限": "111\/05\/04",
    "主成分略述": "palbociclib",
    "限制項目": "02輸　入 51免除銜接性臨床試驗",
    "申請商名稱": "1504402200  輝瑞大藥廠股份有限公司",
    "申請商地址": "台北市信義區松仁路100號42、43樓",
    "主製造廠": [
        {
            "": "GERMANY",
            "製程": "製造、包裝"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013006000",
            "成分名稱": "palbociclib",
            "含量描述": "",
            "含量": "125.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "21.7+\/-0.3mm",
        "特殊劑型": "",
        "顏色": "膠囊體蓋皆淡褐色",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "白色PBC125",
        "標記二": "白色Pfizer"
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Ibrance_125_appearance-107-09-20(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027104&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "1. 0209-Ibrance 愛乳適膠囊 中文仿單-180x700mm-111-04-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027104&Seq=011&Type=9"
        },
        {
            "title": "Ibrance 125mg_7S-110-08-06(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027104&Seq=009&Type=8"
        },
        {
            "title": "Ibrance 125mg_7S-110-01-20(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027104&Seq=008&Type=8"
        },
        {
            "title": "Ibrance 125_BLS07_BLS21_BTL21_201810-107-12-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027104&Seq=007&Type=8"
        },
        {
            "title": "Ibrance 125mg-Lab-060508 tr-106-05-15.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027104&Seq=003&Type=8"
        },
        {
            "title": "Ibrance 125mg-Foil-060508 tr-106-05-15.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027104&Seq=002&Type=8"
        },
        {
            "title": "Ibrance 125mg-CTN-060511 tr-106-05-15.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027104&Seq=001&Type=8"
        }
    ]
}